← Back to Search

Exercise for Chronic Kidney Disease

N/A

Recruiting

Research Sponsored by University of North Texas, Denton, TX

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Individuals with chronic kidney disease stages III-IV.

• Individuals with chronic kidney disease stages III-IV.

Must not have

Uncontrolled hypertension or hypotension

Chronic obstructive pulmonary disease

Timeline

Screening 3 weeks

Treatment Varies

Follow Up mean arterial pressure-middle cerebral artery blood velocity transfer function phase (radians) and gain (cm/s/mmhg) will be compared at baseline (week 0) and after completing the 12-week intervention (week 13).

Summary

This trial will test if regular exercise may help improve how well the brain regulates blood flow in CKD patients.

Who is the study for?

This trial is for people with moderate to severe chronic kidney disease (stages III-IV). It's not suitable for those with heart failure, lung issues like COPD, uncontrolled blood pressure problems, pregnant women or those planning pregnancy, and individuals already exercising regularly.

What is being tested?

The study is looking at how regular exercise might help the brain control blood flow in patients with chronic kidney disease. Participants will engage in supervised exercise routines including cycling and stretching exercises.

What are the potential side effects?

While specific side effects are not listed for this trial, general risks may include muscle soreness, fatigue from the physical activity, and potential strain on the cardiovascular system due to exercise.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have moderate to severe kidney disease.

Select...

I have moderate to severe kidney disease.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

My blood pressure is not stable.

Select...

I have chronic obstructive pulmonary disease.

Select...

I have heart failure.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ mean arterial pressure-middle cerebral artery blood velocity transfer function phase (radians) and gain (cm/s/mmhg) will be compared at baseline (week 0) and after completing the 12-week intervention (week 13).

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~mean arterial pressure-middle cerebral artery blood velocity transfer function phase (radians) and gain (cm/s/mmhg) will be compared at baseline (week 0) and after completing the 12-week intervention (week 13).

This trial's timeline: 3 weeks for screening, Varies for treatment, and mean arterial pressure-middle cerebral artery blood velocity transfer function phase (radians) and gain (cm/s/mmhg) will be compared at baseline (week 0) and after completing the 12-week intervention (week 13). for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Brain Concussion

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Exercise TrainingExperimental Treatment1 Intervention

Participants will exercise 3 times a week on a stationary bicycle. Exercise intensity will begin at low levels (50% of maximal heart rate reserve) and increase as tolerated to a maximum of 80% of maximal heart rate reserve. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes per session.

Group II: StretchingPlacebo Group1 Intervention

Participants will undergo progressive whole body stretching and balance exercises. This type of low intensity exercise is designed not to increase heart rate but rather to improve joint mobility and the ability to perform activities of daily living. This will serve as the control group to the exercise group. The control group will come in for stretching sessions 3 times per week for 20-45 minutes.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Exercise

2016

Completed Phase 1

~820

0 / 5Eligibility criteria met